NDAINHALATIONSUSPENSION
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
8
Mechanism of Action
Phosphodiesterase 3 Inhibitors
Pharmacologic Class:
Phosphodiesterase 3 Inhibitor
Clinical Trials (5)
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Started Oct 2025
33 enrolled
Chronic Obstructive Pulmonary Disease
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Started Jul 2025
480 enrolled
Chronic Obstructive Pulmonary Disease
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Started Sep 2024
180 enrolled
Non-cystic Fibrosis Bronchiectasis
Effect of Ensifentrine Treatment on CAT Score
Started Jun 2024
20 enrolled
COPD
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Started May 2022
56 enrolled
COPD
Loss of Exclusivity
LOE Date
Jun 25, 2044
222 months away
Patent Expiry
Jun 25, 2044
Exclusivity Expiry
Jun 26, 2029